LRMR
Larimar Therapeutics, Inc. NASDAQ Listed Jun 19, 2014$4.00
Mkt Cap $341.9M
52w Low $1.73
48.3% of range
52w High $6.42
50d MA $4.78
200d MA $4.01
P/E (TTM)
-1.7x
EV/EBITDA
-1.1x
P/B
3.7x
Debt/Equity
0.1x
ROE
-212.2%
P/FCF
-2.5x
RSI (14)
—
ATR (14)
—
Beta
1.02
50d MA
$4.78
200d MA
$4.01
Avg Volume
4.2M
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Three Bala Plaza East · Bala Cynwyd, PA 19004 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | BMO | — | — | — | 4.00 | +0.5% | -0.8% | — | — | — | — | — |
| May 7, 2026 | BMO | — | — | — | 4.15 | -0.7% | -3.6% | — | — | — | — | — |
| May 4, 2026 | BMO | — | — | — | 3.94 | -0.3% | +7.1% | -5.0% | +3.5% | -3.6% | — | — |
| Mar 19, 2026 | BMO | -0.44 | -0.73 | -65.9% | 4.30 | -0.7% | +4.0% | +0.4% | +4.2% | -2.4% | +2.4% | — |
| Nov 5, 2025 | BMO | -0.39 | -0.61 | -56.4% | 3.80 | -4.2% | -15.3% | +7.8% | -0.3% | +2.6% | +2.3% | — |
| Aug 14, 2025 | BMO | -0.47 | -0.41 | +12.8% | 3.72 | -0.3% | +14.5% | -5.9% | -2.7% | -6.4% | +3.3% | — |
| Apr 30, 2025 | BMO | -0.42 | -0.46 | -9.5% | 2.39 | +0.4% | +10.9% | +7.9% | +3.8% | -9.4% | -21.9% | — |
| Mar 24, 2025 | BMO | -0.29 | -0.45 | -55.2% | 2.54 | +2.4% | -10.2% | +1.3% | -2.6% | +6.7% | -2.1% | — |
| Oct 30, 2024 | BMO | -0.37 | -0.24 | +35.1% | 7.78 | +5.3% | +8.7% | -2.7% | -6.0% | -2.2% | -2.8% | — |
| Aug 7, 2024 | BMO | -0.32 | -0.34 | -6.2% | 7.65 | +1.0% | -6.5% | +4.1% | +3.2% | -0.8% | -0.7% | — |
| May 9, 2024 | BMO | -0.24 | -0.27 | -12.5% | 7.92 | -1.3% | -0.8% | -9.4% | +2.8% | +7.7% | -0.1% | — |
| Mar 14, 2024 | BMO | -0.25 | -0.30 | -20.0% | 9.30 | -2.6% | -6.5% | +0.0% | -4.0% | +2.9% | -0.7% | — |
| Nov 14, 2023 | BMO | -0.23 | -0.21 | +8.7% | 2.39 | +0.4% | +7.1% | +14.5% | +5.5% | +6.5% | -4.6% | — |
| Aug 10, 2023 | BMO | -0.21 | -0.19 | +9.5% | 4.00 | +2.2% | -4.8% | +2.4% | +8.5% | -1.2% | -4.1% | — |
| May 15, 2023 | BMO | -0.25 | -0.15 | +40.0% | 5.06 | -20.4% | -29.1% | +1.7% | +1.1% | +2.2% | -2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | Wedbush | Maintains | Outperform → Outperform | — | $4.47 | $4.52 | +1.1% | +0.4% | +4.2% | -2.4% | +2.4% | +3.6% |
| Mar 3 | Wedbush | Maintains | Outperform → Outperform | — | $5.23 | $5.58 | +6.7% | +5.4% | -1.1% | -4.2% | +0.0% | +9.0% |
| Feb 25 | Wedbush | Maintains | Outperform → Outperform | — | $3.69 | $3.66 | -0.8% | +61.2% | -7.2% | -3.8% | -1.5% | +5.4% |
| Feb 25 | Citigroup | Maintains | Buy → Buy | — | $3.69 | $3.66 | -0.8% | +61.2% | -7.2% | -3.8% | -1.5% | +5.4% |
| Oct 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.15 | $4.22 | +1.7% | +3.1% | +13.8% | -1.2% | -1.9% | +2.1% |
| Sep 30 | Baird | Maintains | Outperform → Outperform | — | $3.38 | $3.33 | -1.5% | -4.4% | +28.5% | +3.1% | +13.8% | -1.2% |
| Sep 30 | Wedbush | Maintains | Outperform → Outperform | — | $3.38 | $3.33 | -1.5% | -4.4% | +28.5% | +3.1% | +13.8% | -1.2% |
| Aug 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.90 | $3.96 | +1.5% | -6.4% | +3.3% | -2.1% | +6.0% | -4.9% |
| Aug 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.26 | $4.32 | +1.4% | -5.9% | -2.7% | -6.4% | +3.3% | -2.1% |
| Jun 25 | Guggenheim | Maintains | Buy → Buy | — | $2.99 | $3.04 | +1.7% | +8.7% | -5.2% | -1.6% | -4.6% | -0.3% |
| Jun 24 | Wedbush | Maintains | Outperform → Outperform | — | $2.42 | $2.56 | +5.8% | +23.6% | +8.7% | -5.2% | -1.6% | -4.6% |
| Jun 24 | Guggenheim | Maintains | Buy → Buy | — | $2.42 | $2.56 | +5.8% | +23.6% | +8.7% | -5.2% | -1.6% | -4.6% |
| Mar 25 | Baird | Maintains | Outperform → Outperform | — | $2.28 | $2.28 | +0.0% | +1.3% | -2.6% | +6.7% | -2.1% | -8.5% |
| Mar 25 | Guggenheim | Maintains | Buy → Buy | — | $2.28 | $2.28 | +0.0% | +1.3% | -2.6% | +6.7% | -2.1% | -8.5% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.28 | $2.28 | +0.0% | +1.3% | -2.6% | +6.7% | -2.1% | -8.5% |
| Jan 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.63 | $3.73 | +2.8% | -1.4% | -3.4% | +0.6% | +6.6% | +7.0% |
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.83 | $4.71 | -2.5% | -10.6% | -3.7% | -4.3% | +0.8% | -1.2% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.17 | $3.95 | -36.0% | -21.7% | -10.6% | -3.7% | -4.3% | +0.8% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.69 | $6.53 | -2.4% | -7.9% | +3.6% | -4.7% | +0.8% | +0.5% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.46 | $8.47 | +0.1% | -2.7% | -6.0% | -2.2% | -2.8% | +10.9% |
| May 31 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.10 | $7.39 | +4.1% | +12.7% | +14.2% | +4.0% | +4.0% | -3.9% |
| May 22 | Citigroup | Maintains | Buy → Buy | — | $7.89 | $7.89 | +0.0% | +0.1% | -5.4% | -5.2% | +4.2% | -4.2% |
| May 21 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.27 | $8.05 | +10.7% | +8.5% | +0.1% | -5.4% | -5.2% | +4.2% |
| Mar 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.70 | $8.41 | -3.3% | +0.0% | -4.0% | +2.9% | -0.7% | +0.4% |
| Mar 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.63 | $8.81 | +2.1% | +1.6% | +6.0% | -6.5% | +0.0% | -4.0% |
| Feb 13 | Citigroup | Maintains | Buy → Buy | — | $7.83 | $8.06 | +2.9% | +11.6% | +36.8% | +11.0% | -3.8% | -5.6% |
| Feb 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.83 | $8.06 | +2.9% | +11.6% | +36.8% | +11.0% | -3.8% | -5.6% |
| Nov 17 | Citigroup | Upgrade | Neutral → Buy | — | $3.09 | $3.25 | +5.2% | +6.5% | -4.6% | -1.9% | +7.8% | +5.4% |
| Aug 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.23 | $4.20 | -0.7% | -1.2% | -4.1% | -1.5% | -2.0% | +2.1% |
| Jun 20 | JMP Securities | Maintains | Market Outperform → Outperform | — | $3.30 | $3.30 | +0.0% | +5.5% | -0.3% | -3.2% | -1.5% | -1.8% |
| Jun 8 | Citigroup | Maintains | Neutral → Neutral | — | $3.70 | $3.71 | +0.3% | -5.1% | +4.0% | +3.6% | -1.6% | -0.8% |
| May 18 | Citigroup | Maintains | Neutral → Neutral | — | $3.69 | $3.61 | -2.2% | +2.2% | -2.9% | -0.8% | -0.3% | +1.1% |
| May 17 | Guggenheim | Maintains | Buy → Buy | — | $3.65 | $3.74 | +2.5% | +1.1% | +2.2% | -2.9% | -0.8% | -0.3% |
| May 16 | JMP Securities | Maintains | Market Outperform → Outperform | — | $3.59 | $3.60 | +0.3% | +1.7% | +1.1% | +2.2% | -2.9% | -0.8% |
| May 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.59 | $3.60 | +0.3% | +1.7% | +1.1% | +2.2% | -2.9% | -0.8% |
| May 15 | Citigroup | Maintains | Neutral → Neutral | — | $5.06 | $4.03 | -20.4% | -29.1% | +1.7% | +1.1% | +2.2% | -2.9% |
| Mar 15 | Guggenheim | Maintains | Buy → Buy | — | $5.90 | $5.87 | -0.5% | -1.9% | +1.0% | -8.0% | -10.2% | -1.7% |
| Mar 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.73 | $5.98 | +4.4% | +3.0% | -1.9% | +1.0% | -8.0% | -10.2% |
| Mar 1 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.06 | $6.44 | +6.3% | -4.0% | +8.2% | -0.6% | -5.0% | -0.3% |
| Jan 24 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.24 | $4.24 | +0.0% | +0.0% | +0.5% | -1.4% | +11.2% | +3.4% |
| Dec 13 | Citigroup | Maintains | Neutral → Neutral | — | $3.89 | $3.93 | +1.0% | +2.1% | +12.8% | +1.8% | -1.8% | +12.7% |
| Oct 19 | Guggenheim | Maintains | Buy → Buy | — | $3.45 | $3.59 | +4.1% | -0.6% | -2.9% | +0.6% | -12.5% | +2.0% |
| Sep 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.20 | $3.46 | +8.1% | +0.6% | -0.3% | +7.5% | -5.5% | +6.1% |
| Sep 19 | William Blair | Upgrade | Market Perform → Outperform | — | $3.20 | $3.46 | +8.1% | +0.6% | -0.3% | +7.5% | -5.5% | +6.1% |
| Feb 15 | William Blair | Downgrade | Outperform → Market Perform | — | $8.37 | $3.05 | -63.6% | -52.1% | -1.7% | -1.0% | -4.6% | -1.9% |
| Feb 1 | William Blair | Maintains | Outperform → Outperform | — | $15.71 | $16.31 | +3.8% | +8.2% | +11.6% | +3.6% | -3.8% | -2.0% |
No insider trades available.
8-K
Unknown — 8-K Filing
Larimar reported 2025 results as a clinical-stage biotech with no approved products, making cash burn and upcoming financing needs critical metrics that will likely determine stock viability through key development milestones.
Mar 19
8-K · 8.01
!! High
Larimar Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Larimar Therapeutics updated its investor presentation, signaling ongoing engagement with capital markets stakeholders regarding company strategy and operational developments.
Mar 9
8-K
Larimar Therapeutics, Inc. -- 8-K Filing
Larimar Therapeutics completed a securities offering with Citizens JMP Securities as lead manager and JonesTrading as co-manager, indicating the company raised capital through institutional channels.
Feb 27
8-K · 8.01
!! High
Larimar Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Larimar Therapeutics received FDA Breakthrough Therapy Designation for nomlabofusp treating Friedreich's ataxia, accelerating development and review timelines for this rare genetic neurological disorder therapy.
Feb 24
Data updated apr 25, 2026 7:52pm
· Source: massive.com